±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 504  |  »Ø¸´: 0
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£

zhangyong8107

ľ³æ (СÓÐÃûÆø)

[½»Á÷] ¶¡ÂÝ»·ÍªÓëÅÁÂÞÎ÷Í¡ÁªºÏÖÎÁÆÒÖÓôÖ¢µÄÁÙ´²Ñо¿

¡¾ÕªÒª¡¿  Ä¿µÄ  Ì½ÌÖ¶¡ÂÝ»·ÍªÓëÅÁÂÞÎ÷Í¡ÁªºÏÖÎÁÆÒÖÓôÖ¢µÄÁÆÐ§¡£ ·½·¨  ·ûºÏICD-10»òCCMD-3ÒÖÓôÖ¢µÄÕï¶Ï±ê×¼µÄÃÅÕïºÍסԺ²¡ÈË79Àý£¬Ëæ»ú·Ö³ÉÁ½×飬·Ö±ðÓö¡ÂÝ»·ÍªÁªºÏÅÁÂÞÎ÷Í¡ºÍµ¥ÓÃÅÁÂÞÎ÷Í¡ÖÎÁÆ6ÖÜ£¬²ÉÓúºÃܶû¶ÙÒÖÓôÁ¿±í£¨HAMD£©¡¢ººÃܶû¶Ù½¹ÂÇÁ¿±í£¨HAMA£©ÆÀ¶¨ÁÆÐ§£¬Óø±·´Ó¦Á¿±í£¨TESS£©ÆÀ¶¨¸±·´Ó¦¡£ ½á¹û  6ÖÜÄ©ÁªºÏ×éHAMDºÍHAMAÆÀ·ÖµÍÓÚµ¥ÓÃ×é¡£ÔÚµÚ2ÖÜÄ©¡¢µÚ6ÖÜÄ©ÁªºÏ×éµÄHAMDºÍHAMAµÄƽ¾ù¼õ·ÖÂʸßÓÚµ¥ÓÃ×é¡£Á½×é¼äµÄ¸±·´Ó¦Çé¿öÏà·Â¡£ ½áÂÛ  ¶¡ÂÝ»·ÍªÁªºÏÅÁÂÞÎ÷Í¡ÖÎÁÆÒÖÓôÖ¢µÄÁÆÐ§ÓÅÓÚµ¥ÓÃÅÁÂÞÎ÷Í¡¡£


¡¡¡¡¡¾¹Ø¼ü´Ê¡¿  ¶¡ÂÝ»·Íª£»   ÅÁÂÞÎ÷Í¡£»     ÒÖÓôÖ¢


¡¡¡¡A comparative study of buspirone mixed paroxetine in the treatment of depression


¡¡¡¡LIN Zhao-wu, SUN Guo-ping. Qingdao Mental Health Center, Shandong 266034,China.


¡¡¡¡¡¾Abstract¡¿  Objective  To study the efficacy of buspirone mixed paroxetine on depression.Methods  79 cases of outpatients and inpatients with the depression diagnosed according to ICD-10 or CCMD-3 were divided into two groups randomly. The two groups were treated with buspirone mixed paroxetine and single paroxetine respectively for six weeks. The efficacy was measured with Hamiltion Depression Scale (HAMD) and Hamiltion Anxiety Scale (HAMA). The side effects were assessed by the Treatment Emergent Symptom Scale(TESS).Results  The HAMD and HAMA scale in buspirone mixed paroxetine therapy group was significantly lower than single paroxetine group on six weekend. The reduce rate of mean score of HAMA and HAMD in combined group was significantly higher than single group. Two groups of side effects was similar. Conclusion  Buspirone mixed paroxetine therapy was better effect in treatment of depression.


¡¡¡¡¡¾Key words¡¿  buspirone;   paroxetine;   depression


¡¡¡¡¶¡ÂÝ»·ÍªÊÇÒ»ÖÖÐÂÐÍ¿¹½¹ÂÇÒ©£¬ÁÙ´²ÉÏÒÑÓÃÓڹ㷺½¹ÂÇÖ¢£Û1£¬2£ÝºÍ°éÒÖÓôÖ¢×´¡¢½¹ÂÇÖ¢×´µÄÆäËû¼²²¡µÄÖÎÁÆ£Û3£Ý¡£¹úÍâÓв»ÉÙ±¨µÀÈÏΪ¸ÃÒ©¶ÔÒÖÓôÖ¢ÒàÓнϺÃÁÆÐ§£Û4£¬5£Ý¡£±¾ÎÄ̽ÌÖ¶¡ÂÝ»·ÍªÓëÅÁÂÞÎ÷Í¡ÁªºÏÖÎÁÆÒÖÓôÖ¢µÄÁÆÐ§¡£


¡¡¡¡1  ×ÊÁÏÓë·½·¨


¡¡¡¡1£®1  Ò»°ã×ÊÁÏ  Ñо¿¶ÔÏóÀ´Ô´ÓÚÇൺÊо«ÉñÎÀÉúÖÐÐÄ2004Äê3Ô¡«2004Äê8ÔµÄÃÅÕïºÍסԺ²¡ÈË£¬Èë×é±ê×¼:ÄêÁä15¡«65Ë꣬·ûºÏICD-10»òCCMD-3ÒÖÓôÖ¢µÄÕï¶Ï±ê×¼£¬HamiltonÒÖÓôÁ¿±í£¨HAMD£©ÆÀ¶¨18·ÖÒÔÉÏ¡£ÅųýÓÐÑÏÖØÐÄÄÔѪ¹Ü¼²²¡¡¢¸ÎÉö¼²²¡µÈÑÏÖØÇûÌå¼²²¡µÄ»¼Õß¡£¹²79Àý£¬Ëæ»ú·Ö³ÉÁ½×飬һ×éΪ¶¡ÂÝ»·ÍªÓëÅÁÂÞÎ÷Í¡ÁªºÏÖÎÁÆ×飨ÁªºÏ×飩40Àý£¬ÄÐ20Àý£¬Å®20Àý£¬Æ½¾ùÄêÁ䣨46.97¡À12.10£©Ë꣬ƽ¾ù²¡³Ì£¨32.27¡À64.87£©Ì죻һ×éΪÅÁÂÞÎ÷Í¡ÖÎÁÆ×飨µ¥ÓÃ×飩39Àý£¬ÄÐ19Àý£¬Å®20Àý£¬Æ½¾ùÄêÁ䣨42.56¡À15.71£©Ë꣬ƽ¾ù²¡³Ì£¨37.06¡À53.24£©Ìì¡£ÒÔÉϸ÷ÏîÁ½×é¼ä²îÒì¾ùÎÞÏÔÖøÐÔ£¨P>0.05£©¡£


¡¡¡¡1.2  ·½·¨  Á½×éÒ©ÎïÇåÏ´ÆÚ¾ùΪ1ÖÜ£¬ÁªºÏ×鏸Óè¶¡ÂÝ»·Íª¹Ì¶¨¼ÁÁ¿30mgºÍÅÁÂÞÎ÷Í¡¹Ì¶¨¼ÁÁ¿20mg£¬µ¥ÓÃ×鏸ÓèÅÁÂÞÎ÷Í¡¹Ì¶¨¼ÁÁ¿20mg/d£¬ÁƳÌΪ6ÖÜ£¬ÖÎÁÆÆÚ¼ä²»µÃºÏ²¢°²¶¨ÀàÒ©Îï¡£Á½×éÔÚÈë×éǰºÍÈë×éºóµÚ1¡¢2¡¢4¡¢6ÖÜ£¬·Ö±ðÓÃHAMD¡¢HAMA¡¢CGI¡¢TESSÁ¿±íÆÀ·Ö£¬ÔÚÖÎÁÆÇ°ºÍÖÎÁƺó½øÐÐѪ¡¢Äò³£¹æ¡¢ÑªÉú»¯ºÍÐĵçͼ¼ì²é¡£


¡¡¡¡1.3  ÁÆÐ§±ê×¼  HAMD¼õ·ÖÂÊ¡Ý75%ΪȬÓú£¬¡Ý50%ΪÏÔÖø½ø²½£¬¡Ý25%Ϊ½ø²½£¬£¼25%ΪÎÞЧ¡£


¡¡¡¡1.4  Í³¼ÆÑ§·½·¨  ËùÓÐ×ÊÁÏÓ¦ÓÃSPSSÈí¼þ½øÐÐͳ¼Æ·ÖÎö¡£


¡¡¡¡2  ½á¹û


¡¡¡¡2£®1  ÁÙ´²ÁÆÐ§  ÁªºÏ×éºÍµ¥ÓÃ×é¾ùÔÚÖÎÁƵÚ2ÖÜÄ©HAMDƽ¾ù¼õ·ÖÂÊ>25%£¬´ïµ½½ø²½£»µÚ6ÖÜĩƽ¾ù¼õ·ÖÂÊ>50%´ïµ½ÏÔÖø½ø²½¡£µÚ6ÖÜÄ©ÁªºÏ×éHAMDºÍHAMA ÆÀ·ÖµÍÓÚµ¥ÓÃ×飬²îÒìÓÐÏÔÖøÐÔ£¨P<0.05£©£»ÔÚµÚ2ÖÜÄ©ÁªºÏ×éµÄHAMDºÍHAMAµÄƽ¾ù¼õ·ÖÂʸßÓÚµ¥ÓÃ×飬²îÒìÓÐÏÔÖøÐÔ£¨P<0.05£©£¬ÔÚµÚ6ÖÜÄ©ÁªºÏ×éµÄHAMDºÍHAMAµÄƽ¾ù¼õ·ÖÂÊÃ÷ÏÔ¸ßÓÚµ¥ÓÃ×飬²îÒìÓзdz£ÏÔÖøÐÔ£¨P<0.01£©£¬¼û±í1¡¢2¡£±í1  ÁªºÏ×éÓëµ¥ÓÃ×éÖÎÁÆÇ°ºóHAMDºÍHAMAÆÀ·Ö±È½Ï  ×¢£º*P<0.05±í2  ÁªºÏ×éÓëµ¥ÓÃ×éÖÎÁÆÇ°ºóHAMDºÍHAMAÆÀ·Ö¼õ·ÖÂʱȽϠ ×¢£º*P<0.05£¬**P<0.01


¡¡¡¡2.2  ²»Á¼·´Ó¦·ÖÎö  ÖÎÁƽáÊøÊ±ÁªºÏ×éTESSÆÀ·ÖΪ£¨2.61¡À1.50£©·Ö£¬µ¥ÓÃ×éΪ£¨2.31¡À1.18£©·Ö,Á½×é¼ä²îÒìÎÞÏÔÖøÐÔ£¨P>0.05£©¡£ÁªºÏ×鸱·´Ó¦ÓÐÍ·ÔΡ¢¶ñÐÄ¡¢±ãÃØºÍʧÃߣ»µ¥ÓÃ×éÒÔ¶ñÐÄ¡¢±ãÃØºÍ½¹ÂÇΪ¶à¡£¼û±í3¡£±í3  Á½×é²»Á¼·´Ó¦µÄ³öÏÖÆµ¶È  


¡¡¡¡3  ÌÖÂÛ  


¡¡¡¡¶¡ÂÝ»·Íª¶Ô5-HT1AÊÜÌåÓÐÑ¡ÔñÐÔÇ׺ÍÁ¦£¬±íÏÖ³öÁ½ÖÖ×÷Ó᪡ªÍêÈ«µÄÍ»´¥Ç°¼¤¶¯¼Á¹¦ÄܺͲ¿·ÖÍ»´¥ºó¼¤¶¯¼Á¹¦ÄÜ£Û4£Ý£¬ÓÉ´ËÍÆ²â£ºÐ¡¼ÁÁ¿Ê¹Óö¡ÂÝ»·ÍªÊ±£¬Í»´¥Ç°5-HT1A×ÔÉíÊÜÌ弤¶¯×÷ÓôóÓÚÍ»´¥ºó5-HT1AÊÜÌ弤¶¯×÷Óã¬Òò¶ø²úÉú¸º·´À¡ÒÖÖÆ×÷Óã¬Ê¹½¹ÂÇÖ¢¹ý¸ßµÄ5-HT»îÁ¦½µµÍ£¬»º½â½¹ÂÇÖ¢×´£»¶ø´ó¼ÁÁ¿Ê¹Óö¡ÂÝ»·Íªºó£¬µ¼Ö¸º·´À¡ÒÖÖÆ×÷ÓüõÉÙ£¬Ê¹Í»´¥ºó¼¤¶¯×÷ÓÃÔöÇ¿£¬Ïà¶ÔµØÌá¸ßÁË5-HTÉñ¾­µÝÖʻ£¬´Ó¶ø²úÉú¿¹ÒÖÓô×÷ÓãÛ6£Ý¡£±¾Ñо¿½á¹û±íÃ÷ÅÁÂÞÎ÷Í¡ÁªºÏ¶¡ÂÝ»·ÍªÖÎÁÆÒÖÓôÖ¢µÄÁÆÐ§ÒªºÃÓÚµ¥ÓÃÅÁÂÞÎ÷Í¡ÖÎÁƵÄÁÆÐ§£¬Óë¹úÄÚÍâµÄ±¨µÀÏàÒ»Ö£Û7£¬8£Ý¡£Õâ³ýÁËÓë¶¡ÂÝ»·Íª±¾ÉíÓп¹ÒÖÓô×÷ÓÃÓйØÒÔÍ⣬»¹Ö÷ÒªÒòΪ¶¡ÂÝ»·Íª¶Ô¿¹ÒÖÓô¼ÁÓÐÔöЧ×÷ÓãÛ7£Ý¡£


¡¡¡¡±¾Ñо¿Í¬Ê±·¢ÏÖÁªºÏµÚ2ÖÜÄ©HAMDºÍHAMAµÄ¼õ·ÖÂÊÒÑ´óÓÚÅÁÂÞÎ÷Í¡×飬Õâ¿ÉÄÜÓë¶¡ÂÝ»·Íª¿¹½¹ÂÇ×÷ÓÃÓйأ¬ËüÊ×ÏȸÄÉÆÁ˲¡È˵Ľ¹ÂÇÖ¢×´£»Æä´Î£¬×èÖÍÖ¢×´»º½â½ÏÂý£Û9£Ý¡£Â½ï£µÈ£Û3£Ý·¢ÏÖ£º¾¡¹ÜËæ×ÅHAMAÏÔÖø¼õÉÙ£¬HAMDÒ²ÔÚ2ÖܺóÓëÖÎÁÆÇ°¶Ô±È·¢ÉúÏÔÖøÐÔ²îÒ죬µ«ÒÖÓôµÄºËÐÄÖ¢×´¡ª¡ª×èÖÍÖ¢×´¡ª¡ª²¢Î´Ñ¸ËÙ»º½â£¬¶øÊǾ­¹ý4Öܺó²ÅÏÔÖø¼õ·Ö£¬ËµÃ÷»¼ÕßµÄÒÖÓô֢״ûÓÐËæ×Ž¹ÂǵĿØÖƶø×ÔÈ»»º½â£¬ÕâÓë±¾ÎĽá¹ûÏàÒ»Ö¡£Á½×鲡ÈËÔÚÖÎÁƵĵÚ4ÖÜÒòΪÒÖÓôµÄºËÐÄÖ¢×´¿ÉÄܼÌÐø´æÔÚ£¬HAMDµÄ¼õ·ÖÂʲîÒìÎÞÏÔÖøÐÔ£»µ«ÊÇÔÚµÚ6ÖÜÓÉÓÚ¶¡ÂÝ»·ÍªµÄ¿¹ÒÖÓô×÷Ó㬻òÕßÊǶÔÅÁÂÞÎ÷Í¡µÄÔöЧ×÷Óã¬ÏÔʾÁËÁªºÏÖÎÁƵÄÁ¼ºÃÁÆÐ§¡£


¡¡¡¡Óö¡ÂÝ»·ÍªÖÎÁƵIJ¡ÈËÔ¼67%¡«88%δ³öÏÖÈκβ»Á¼·´Ó¦£¬¸±·´Ó¦½ÏÉÙ½ÏÇᣬÖ÷ÒªÓУºÍ·ÔΣ¨6.6%£©¡¢Í·Í´£¨4.9%£©£¬Î¸³¦¹¦ÄÜÎÉÂÒ£¨6.0%£©ºÍʧÃߣ¨3.8%£©¡£±¾Ñо¿·¢ÏÖ²¢Ã»ÓÐÒòΪºÏ²¢ÓÃÒ©£¬¶øÔö¼ÓÒ©ÎïµÄ¸±·´Ó¦£»ÁªºÏ×éÓÐ5Àý£¨15.2%£©³öÏÖ¶ñÐÄ£¬3Àý(9.09%)ÓÐÍ·ÔΣ¬3Àý£¨9.09%£©ÓбãÃØ£¬ÕâÓë÷ÆäÒ»µÈ£Û8,9£Ý±¨µÀµÄ½á¹û±È½ÏÒ»Ö¡£


¡¡¡¡±¾Ñо¿½á¹û±íÃ÷£¬¶¡ÂÝ»·ÍªÁªºÏÅÁÂÞÎ÷Í¡ÖÎÁÆÒÖÓôÖ¢£¬¿ÉÄܼӿìÆðЧµÄʱ¼ä£¬ÓÈÆäÊǶ԰éÓÐÃ÷ÏÔ½¹ÂÇÖ¢µÄ»¼Õߣ¬ÄܲúÉú½ÏºÃµÄÖÎÁÆÐ§¹û¡£


¡¡¡¡¡¾²Î¿¼ÎÄÏס¿


¡¡¡¡1  ÖìÔ¾»ª.¶¡ÂÝ»·ÍªÖÎÁƹ㷺ÐÔ½¹ÂÇÖ¢ÁÙ´²¶ÔÕÕÑо¿.ÁÙ´²¾«ÉñҽѧÔÓÖ¾, 2000£¬1£º20.


¡¡¡¡2  ¿öÀû£¬ÑîµÂÀ¼£¬Áèºç.¶¡ÂÝ»·ÍªÖÎÁƹ㷺ÐÔ½¹ÂÇÖ¢µÄÏà¹ØÑо¿.ÖйúÉñ¾­¾«Éñ¼²²¡ÔÓÖ¾£¬2001£¬27(4)£º295.


¡¡¡¡3  Â½ï££¬Ëï»Û·¼£¬Öܾý¸»£¬µÈ.¶¡ÂÝ»·ÍªÖÎÁưéÒÖÓôÖ¢×´½¹ÂÇÖ¢µÄÁÙ´²Ñо¿.ÉϺ£¾«Éñҽѧ£¬1999£¬2£º88.


¡¡¡¡4  Robinson DS. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis in the treatment of depression. J Clin Psychopharmacol, 1990, 10: 67-76.


¡¡¡¡5  Rickels K. Buspirone in major depression: a controlled study. J Clin Psychiatry, 1991,52(1): 34-38.


¡¡¡¡6  Ð»±ó£¬Íõ׿³Ð.¿¹½¹ÂÇÐÂÒ©¡ª¶¡ÂÝ»·ÍªµÄÑо¿ÓëÓ¦ÓÃÏÖ×´.¹úÍâҽѧ¡¤¾«Éñ²¡Ñ§·Ö²á£¬1993£¬1£º20.


¡¡¡¡7  De Battista C, Sofuoglu M,Schatzberg AF. Serotonergic synergism: The risk and benefits of combining the selective serotomin reuptake inhibitors with other serotonergic drugs. Biol Psychiatry, 1998,44: 34.


¡¡¡¡8  Stahl SM. Essential Psychopharmacology. Second Edition.Cambridge University Press£¬ 2000£¬273.


¡¡¡¡9  Ã·ÆäÒ»£¬ÍõÏþÁú.¶¡ÂÝ»·Íª¿ª·ÅÖÎÁƽ¹ÂÇÖ¢19ÀýÁÙ´²·ÖÎö.ÁÙ´²¾«ÉñҽѧÔÓÖ¾£¬1998£¬6:332.


¡¡¡¡×÷Õßµ¥Î»£º 266034 ɽ¶«Çൺ£¬ÇൺÊо«ÉñÎÀÉúÖÐÐÄ
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ zhangyong8107 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 285Çóµ÷¼Á +15 ŶßϺôo 2026-04-04 17/850 2026-04-06 23:02 by chenzhimin
[¿¼ÑÐ] ¹¤¿Æ 22408 267ÇóÍÆ¼ö +4 wanwan00 2026-04-05 5/250 2026-04-06 22:47 by chenzhimin
[¿¼ÑÐ] 288Çóµ÷¼Á +9 ûÓдð°¸_ 2026-04-05 9/450 2026-04-06 22:45 by chenzhimin
[¿¼ÑÐ] 307Çóµ÷¼Á +3 ËùÄî¼°ËùÍû 2026-04-06 3/150 2026-04-06 17:30 by ÍÁľ˶ʿÕÐÉú
[¿¼ÑÐ] 270·ÖÇóµ÷¼Á +5 maxjxbsk 2026-04-01 5/250 2026-04-06 15:32 by lin-da
[¿¼ÑÐ] 308Çóµ÷¼Á +13 ÌÈÈôÆð·çÁËÄØ 2026-04-05 13/650 2026-04-06 14:20 by ½¯ð©Óí
[¿¼ÑÐ] 0854Çóµ÷¼Á +4 assdll 2026-04-05 4/200 2026-04-06 12:29 by ÖзÉÔº¿Õ¹ÜѧԺÑ
[¿¼ÑÐ] µÚÒ»Ö¾Ô¸¶«ÄÏ´óѧÎïÀí313£¬ÓпÆÑоºÈü»ñ½±¾­Àú£¬Ï£ÍûÎïÀí¸´ÊÔµ÷¼Á +3 ÂíÄÚ³È 2026-04-05 3/150 2026-04-06 10:32 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 295Çóµ÷¼Á +8 FZAC123 2026-04-03 8/400 2026-04-05 17:46 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 298·Ö 070300Çóµ÷¼Á +15 zwen03 2026-04-02 15/750 2026-04-05 12:52 by Hdyxbekcb
[¿¼ÑÐ] 0832ʳƷ¿ÆÑ§Ó빤³Ìѧ˶282µ÷¼Á +6 ÓãÔÚË®ÖÐÓÎa 2026-04-02 9/450 2026-04-05 11:45 by flysky1234
[¿¼ÑÐ] ר˶310Çóµ÷¼Á +5 ÀÌÀÌÎÒ¡­. 2026-04-04 6/300 2026-04-04 23:33 by barlinike
[¿¼ÑÐ] 085400µç×ÓÐÅÏ¢319Çóµ÷¼Á£¨½ÓÊÜ¿çרҵµ÷¼Á£© +5 ÐÇÐDz»Õ£ÑÛà¶ 2026-04-03 6/300 2026-04-04 21:50 by hemengdong
[¿¼ÑÐ] 359Çóµ÷¼Á +7 hhhhaaaa$ 2026-04-04 7/350 2026-04-04 18:49 by imissbao
[¿¼ÑÐ] ר˶ 351 086100 Ò²ÊÇ¿¼µÄ²Ä¿Æ»ù ±¾¿ÆÒ²ÊDzÄÁÏ +8 202451007219 2026-04-02 8/400 2026-04-03 09:50 by À¶ÔÆË¼Óê
[¿¼²©] É격ÇóÖú +3 Reee1Llll 2026-04-01 3/150 2026-04-02 22:29 by ÕâÊÇÒ»¸öÎÞÁĵÄê
[¿¼ÑÐ] Ò»Ö¾Ô¸ÏÃÃÅ´óѧ»¯Ñ§¹¤³Ì£¨×¨Ë¶£©-Êý¶þÓ¢¶þ406·Ö-Çóµ÷¼Á +5 Ïô󻯹¤ 2026-04-01 5/250 2026-04-02 10:03 by jp9609
[¿¼ÑÐ] ²ÄÁÏÇóµ÷¼Á +10 ÄØÄØÄÝÄÝ 2026-04-01 13/650 2026-04-02 09:17 by olim
[¿¼ÑÐ] 085602»¯Ñ§¹¤³Ì268·Ö¶×µ÷¼Á +8 ÔÂÕÕ»¨ÁÖ¡£ 2026-04-01 8/400 2026-04-01 22:08 by Î޼ʵIJÝÔ­
[˶²©¼ÒÔ°] ²©Ò»±»ËͳöÁªÅà¸Ð¾õ²»ÊÊÓ¦Ôõô°ì +3 È«´åµÄ¹· 2026-03-31 3/150 2026-04-01 10:44 by 328838485
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û